VCAM1 and B-cell chronic lymphocytic leukemia: Here, by taking advantage of both in vitro and in vivo ibrutinib-treated CLL cells, we could confirm the relationship between ibrutinib exposure and impaired CLL cell adhesion on VCAM-1 substrates (which was more apparent in cells derived from in vivo treatment), with increased inhibition after 30 d of therapy.